Colloidal Selenium Antiviral Agent for Broad-Spectrum RNA Virus Protection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiviral drugs are limited in their ability to prevent viral infections caused by RNA-containing viruses with a lipid capsid, as they often target specific serotypes and do not effectively suppress viruses intracellularly, especially in immunodeficiency conditions.
Innovation Solution
A preventive agent containing viral material from RNA-containing viruses combined with stabilized colloidal selenium, which activates completed phagocytosis to suppress viruses regardless of serotypes or antigenic composition, using a 1:1 weight ratio of viral material to colloidal selenium with particle sizes between 10 nm and 40 nm.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If specific vaccines are used to prevent viral infections, then protection against specific serotypes is achieved, but broad-spectrum protection against different virus types is not provided
Solution Approach 1:
The patent applies universality by creating a vaccine composition that provides broad-spectrum protection against multiple serotypes of RNA-containing viruses with lipid capsids. The composition uses viral material from different serotypes combined with stabilized colloidal selenium, enabling a single vaccine to protect against various virus types (influenza, transmissible gastroenteritis, etc.) rather than requiring separate vaccines for each serotype.
Solution Approach 2:
The patent employs composite materials by combining viral material from RNA-containing viruses with stabilized colloidal selenium. This composite composition enhances the immunogenicity and protective efficacy against multiple virus serotypes, creating a more versatile preventive agent than single-component vaccines.
2Reliability
If conventional antiviral drugs are used, then specific serotype targeting is achieved, but intracellular virus suppression is not effective
Solution Approach 1:
The patent applies parameter changes by utilizing stabilized colloidal selenium with specific particle size parameters (colloidal form) to enhance intracellular virus suppression. The selenium's physical state and size parameters are optimized to improve its ability to suppress viruses intracellularly, providing a simpler mechanism compared to complex antiviral drug pathways.
3Adaptability or versatility
If plant extracts are used as antiviral agents, then multi-component effects are achieved, but specific antiviral activity is diluted
Solution Approach 1:
The patent applies extraction by isolating and using specific viral material from RNA-containing viruses with lipid capsids, rather than using whole plant extracts. This extraction approach concentrates the antiviral components, providing specific and reliable antiviral activity while maintaining the ability to protect against multiple serotypes through the selected viral material and selenium combination.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The agent provides effective protection against viral diseases by activating phagocytic cells to capture and digest viral particles, reducing viral titers and minimizing the production of specific antibodies, thus offering broad-spectrum protection at minimal cost with a single or double injection.
Implementation Method 1
The agent activates the completed phagocytosis of viruses, without increasing the titer of specific viral neutralizing antibodies
Data Source
AI summary
The invention relates to medicine and veterinary medicine, and more specifically to pharmacology, and can be used to prevent viral infections caused be RNA viruses that have a lipid capcid. An agent for prevention viral infections comprises viral material from RNA viruses that have a lipid capcid and stabilized colloidal selenium at a 1:1 ratio. The viral material from RNA viruses has titres of 6.0-8.0 lg TCD50/ml. To obtain colloidal selenium having particle sizes from 10 to 15 nm the colloidal selenium is stabilized with polyethylene glycol, and for colloidal selenium having particle sizes from 20 to 40 nm, the colloidal selenium is stabilized with cysteine.